Triptolide inhibits histone methyltransferase EZH2 and modulates the expression of its target genes in prostate cancer cells

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 10, 2013, Pages 5663-5669

  Tamgue, Ousman ^a,b   Chai, Cheng Sen ^a   Hao, Lin ^a   Zambe, John Clotaire Daguia ^a   Huang, Wei Wei ^a   Zhang, Bin ^a   Lei, Ming ^a   Wei, Yan Ming ^a  

^a NORTHWEST A F UNIVERSITY   (China)

^b UNIVERSITY OF YAOUNDÉ I   (Cameroon)

Author keywords

EZH2; EZH2 target genes; Prostate cancer (PCa); Triptolide

Indexed keywords

DITERPENE; EPOXIDE; EZH2 PROTEIN, HUMAN; HISTONE LYSINE METHYLTRANSFERASE; HISTONE METHYLTRANSFERASE; MESSENGER RNA; PHENANTHRENE DERIVATIVE; POLYCOMB REPRESSIVE COMPLEX 2; TRIPTOLIDE;

CELL PROLIFERATION; DOWN REGULATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; PROSTATIC NEOPLASMS; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; DITERPENES; DOWN-REGULATION; EPOXY COMPOUNDS; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; MALE; PHENANTHRENES; POLYCOMB REPRESSIVE COMPLEX 2; PROSTATIC NEOPLASMS; RNA, MESSENGER;

EID: 84890462644     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.10.5663     Document Type: Article

References (37)

1. AntonoffMB, Chugh R, Borja-Cacho D, et al (2009). Triptolide therapy for neuroblastoma decreases cell viability in vitro and inhibits tumor growth in vivo. Surgery, 146, 282-90.
2. Cao Q, Yu J, Dhanasekaran SM, et al (2008). Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene, 27, 7274-84.
3. Chang CJ, Hung MC (2012). The role of EZH2 in tumour progression. Br J Cancer, 106, 243-7.
4. Chase A, Cross NC (2011). Aberrations of EZH2 in Cancer. Clin Cancer Res, 17, 2613-8.
5. Crea F, Hurt EM, Mathews LA, et al (2011). Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. Mol Cancer, 10, 40.
6. Ellis L, Atadja PW, Johnstone RW (2009). Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther, 8, 1409-20.
7. Etchegaray JP, Yang X, DeBruyne JP, et al (2006). The polycomb group protein EZH2 is required for mammalian circadian clock function. J Biol Chem, 281, 21209-15.
8. Feldman BJ, Feldman D (2001). The development of androgenindependent prostate cancer. Nat Rev Cancer, 1, 34-45.
9. Fussbroich B, Wagener N, Macher-Goeppinger S, et al (2011). EZH2 depletion blocks the proliferation of colon cancer cells. PLoS One, 6, e21651.
10. Gil J, Bernard D, Peters G (2005). Role of polycomb group proteins in stem cell self-renewal and cancer. DNA Cell Biol, 24, 117-25.
11. Huang W, He T, Chai C, et al (2012). Triptolide inhibits the proliferation of prostate cancer cells and down-regulates SUMO-specific protease 1 expression. PLoS One, 7, e37693.
12. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
13. Kamminga LM, Bystrykh LV, de Boer A, et al (2006). The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. Blood, 107, 2170-9.
14. Kiviharju TM, Lecane PS, Sellers RG, et al (2002). Antiproliferative and proapoptotic activities of triptolide (PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells. Clin Cancer Res, 8, 2666-74.
15. Liu J, Jiang Z, Xiao J, et al (2009). Effects of triptolide from Tripterygium wilfordii on ERalpha and p53 expression in two human breast cancer cell lines. Phytomedicine, 16, 1006-13.
16. Min J, Zaslavsky A, Fedele G, et al (2010). An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med, 16, 286-94.
17. O'Carroll D, Erhardt S, Pagani M, et al (2001). The polycombgroup gene Ezh2 is required for early mouse development. Mol Cell Biol, 21, 4330-6.
18. Phillips PA, Dudeja V, McCarroll JA, et al (2007). Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70. Cancer Res, 67, 9407-16.
19. Plath K, Fang J, Mlynarczyk-Evans SK, et al (2003). Role of histone H3 lysine 27 methylation in X inactivation. Science, 300, 131-5.
20. Ren SC, Chen R, Sun YH (2013). Prostate cancer research in China. Asian J Androl, 15, 350-3.
21. Saramäki OR, Tammela TL, Martikainen PM, et al (2006). The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. Genes Chromosomes Cancer, 45, 639-45.
22. Sauvageau M, Sauvageau G (2010). Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell, 7, 299-313.
23. Schulz WA, Hatina J (2006). Epigenetics of prostate cancer: beyond DNA methylation. J Cell Mol Med, 10, 100-25.
24. Shi B, Liang J, Yang X, et al (2007). Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells. Mol Cell Biol, 27, 5105-19.
25. Su IH, Basavaraj A, Krutchinsky AN, et al (2003). Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement. Nat Immunol, 4, 124-31.
26. Su IH, Dobenecker MW, Dickinson E, et al (2005). Polycomb group protein ezh2 controls actin polymerization and cell signaling. Cell, 121, 425-36.
27. Titov DV, Gilman B, He QL, et al (2011). XPB, a subunit of TFIIH, is a target of the natural product triptolide. Nat Chem Biol, 7, 182-8.
28. Varambally S, Dhanasekaran SM, Zhou M, et al (2002). The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature, 419, 624-9.
29. Wang Y, Lu JJ, He L, et al (2011). Triptolide (TPL) inhibits global transcription by inducing proteasome-dependent degradation of RNA polymerase II (Pol II). PLoS One, 6, e23993.
30. Wang Z, Jin H, Xu R, et al (2009). Triptolide downregulates Rac1 and the JAK/STAT3 pathway and inhibits colitisrelated colon cancer progression. Exp Mol Med, 41, 717-27.
31. Westerheide SD, Kawahara TL, Orton K, et al (2006). Triptolide, an inhibitor of the human heat shock response that enhances stress-induced cell death. J Biol Chem, 281, 9616-22.
32. Wu SC, Zhang Y (2011). Cyclin-dependent kinase 1 (CDK1)- mediated phosphorylation of enhancer of zeste 2 (Ezh2) regulates its stability. J Biol Chem, 286, 28511-9.
33. Yu J, Cao Q, Mehra R, et al (2007). Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell, 12, 419-31.
34. Yu J, Yu J, Mani RS, et al (2010). An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell, 17, 443-54.
35. Zhao F, Chen Y, Zeng L, et al (2010). Role of triptolide in cell proliferation, cell cycle arrest, apoptosis and histone methylation in multiple myeloma U266 cells. Eur J Pharmacol, 646, 1-11.
36. Zhao F, Chen Y, Li R, et al (2010). Triptolide alters histone H3K9 and H3K27 methylation state and induces G0/G1 arrest and caspase-dependent apoptosis in multiple myeloma in vitro. Toxicology, 267, 70-9.
37. Zhu W, Ou Y, Li Y, et al (2009). A small-molecule triptolide suppresses angiogenesis and invasion of human anaplastic thyroid carcinoma cells via down-regulation of the nuclear factor-kappa B pathway. Mol Pharmacol, 75, 812-9.